STEM StemCells, Inc. featured news, full reports, and detailed charts
StemCells, Inc. (STEM) Wrap Up:
StemCells, Inc. is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. Our aim is to restore or support organ function, improve patients’ lives and reduce the substantial health care costs associated with these diseases and disorders by identifying and developing stem and progenitor cells as potential therapeutic agents. We currently have product development programs for two cell types: the human neural stem cell and human liver engrafting cells. In our CNS Program, we are conducting a Phase I clinical trial to evaluate the safety and preliminary efficacy of our HuCNS-SC® product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease. We have completed enrollment and dosing in this six-patient trial and expect it to be completed in early 2009. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0000891618-08-000164.html#FIS_BUSINESS"www.stemcellsinc.com
55 Employees
Founded in 1988
StemCells Inc. (STEM:NASDAQ)
LAST $1.09 USD
CHANGE TODAY 0.00 0.00%
VOLUME 785.9K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of StemCells Inc. (STEM)
|
OPEN
$1.12
|
PREVIOUS CLOSE
$1.09
|
|
|
DAY HIGH
$1.13
|
DAY LOW
$1.08
|
|
|
52 WEEK HIGH
01/26/09 - $3.07
|
52 WEEK LOW
11/21/08 - $0.80
|
|
|
MARKET CAP
129.0M
|
AVERAGE VOLUME 3 mo
1.0M
|
|
|
DILUTED EPS TTM
$-0.31
|
SHARES OUTSTANDING
118.4M
|
|
|
STEM Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
STEM Top Compensated Officers
Mr. Martin M. McGlynn
Chief Executive Officer, President, Director,...
Age: 63
Total Annual Compensation: $462.0K
Mr. Rodney K. B. Young
Chief Financial Officer and Vice President of...
Age: 46
Total Annual Compensation: $309.4K
Dr. Ann Tsukamoto Ph.D.
Chief Operating Officer and Executive Vice Pr...
Age: 56
Total Annual Compensation: $337.5K
Mr. Kenneth B. Stratton J.D.
Secretary and General Counsel
Age: 40
Total Annual Compensation: $292.0K
Dr. Stewart Craig Ph.D.
Senior Vice President of Development & Operat...
Age: 47
Total Annual Compensation: $84.1K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for StemCells Inc. (STEM)
StemCells Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/5/2009
StemCells Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company has posted net loss of $5,145,000, or $0.05 basic and diluted per share, compared with a net loss of $5,744,000, or $0.07 basic and diluted per share, in the third quarter of 2008. Total revenue was $253,000, compared to $12,000 for the third quarter of 2008. This revenue growth was primarily driven by the consolidation of the Stem Cell Sciences operations, which were acquired in April 2009. Loss from operations was $6,983,000 compared to $5,845,000 for the same period a year ago. For the nine months, the company has posted total revenue of $575,000 compared to $60,000 for the same period a year ago. Loss from operations was $21,297,000 compared to $19,640,000 for the same period a year ago. Net loss was $21,792,000 or $0.21 basic and diluted per share compared to net income of $19,004,000 or $0.24 basic and diluted per share for the same period a year ago.
StemCells Inc. expected to Report Fiscal Year 2009 Results on March 15, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
11/5/2009
StemCells Inc. expected to Report Fiscal Year 2009 Results on March 15, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
StemCells Inc. Announces Initiatives to Advance Cell-Based Technologies for Pharmaceutical Industry and Research Applications
09/22/2009
StemCells Inc. announced organizational initiatives focused on growing its specialty SC Proven(R) cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company's ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company's Cambridge, UK and Palo Alto, California locations. The Company is leveraging multiple stem cell technology platforms that include embryonic stem cells, induced pluripotent stem cells and tissue-derived (adult) stem cells. StemCells will refocus and add to its research and development of cell-based assays, and better align those efforts with its scale-up and manufacturing of cells and assays for drug screening and drug development, including using its automated cell culture platform that enables large-scale production for medium-throughput screening of drug candidates.
STEM Competitors
| Company | Last | Change |
| Aastrom Biosciences Inc | $0.31 USD | 0.00 |
| Bioheart Inc | $0.89 USD | -0.01 |
| Medistem Inc | $0.19 USD | -0.145 |
| Thermogenesis Corp | $0.62 USD | -0.0125 |
| Titan Pharmaceuticals Inc | $2.26 USD | -0.03 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | STEM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 157.9x |
|
| Price/Book | 4.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 126.5x |
|
|
STEM |
||
|
STEM transactions
| Type Date |
Target |
|
Private Placement
October 28, 2009 |
-- |
More Recent News About StemCells, Inc.
More news for STEM
StemCells, Inc. Reports Third Quarter Financial Results
 StemCells, Inc. Unaudited Condensed Consolidated Statement of Operations (in thousands, except share and per share amounts) (unaudited)       Three months endedSeptember 30, Nine months endedSeptember 30, 2009 2008 2009 2008 Revenue: Revenue from licensing agreements and grants $ 99 $ 12 $ ...Click here to read the whole Article (external link)
STEMCELLS INC Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This report contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act that involve substantial risks and uncertainties. Such statements include, without limitation, all statements as to expectation or belief and statements as to our future results of operations; the progress of our research, product development and clinical programs; the need for, and timing of, additional capital and capital expenditures; partnering prospects; costs of manufacture of products; the protection of, and the need for, additional intellectual property rights; effects of regulations; the need for additional facilities; and potential market opportunities. Our actual results may vary materially from those contained in such forward-looking statements because of risks to which we are subject, including the fact that additional trials will be required to confirm the safety and demonstrate the efficacy of the Company's HuCNS-SC cells for the treatment of neuronal ceroid lipofuscinosis (NCL, also known as Batten disease) or any other disease; uncertainty as to whether the U.S. Food and Drug Administration (FDA) or other regulatory authorities will permit us to proceed with clinical testing of proposed products despite the novel and unproven nature of our technologies; the risk that one or more of our clinical trials or studies could be substantially delayed beyond their expected dates or cause us to incur substantial unanticipated costs; uncertainties in our ability to obtain the capital resources needed to continue our current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; uncertainties about the design of future clinical trials and whether the Company will receive the necessary support of a clinical trial site and its institutional review board to ...Click here to read the whole Article (external link)
STEMCELLS INC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits
Show all filings for STEMCELLS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K/A for STEMCELLS INC 4-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes o...Click here to read the whole Article (external link)
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for STEMCELLS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for STEMCELLS INC 3-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only,...Click here to read the whole Article (external link)
StemCells reports Q3 loss of $5M
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
New Star Analyst Rankings for StemCells, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for STEMCELLS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for STEMCELLS INC 5-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes onl...Click here to read the whole Article (external link)
Can Stem Cells Put an End To Paralysis?
A successful rodent study showed promise for future treatment of spinal injuries. Menlo Park, California-based Geron Corporation (NASDAQ: GERN - News) is trading higher by 6% today after reporting the results of a recent spinal injury study in rodents. Geron used oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs) to reduce tissue damage in the rodent model of cervical spinal cord injury - a process that could potentially limit paralysis in humans.According to the press release, over half of the 11,000 human spinal cord injuries in the U.S. each year are in the cervical region (the neck). Geron president and CEO Dr. Thomas B. Okarma, explained, "These preclinical studies demonstrate that transplantation of hESC-derived OPCs resulted in sparing of spinal cord tissue in the cervical lesion site. This sparing starts very soon after injection and importantly, results in the preservation of motor neurons, which is correlated to recovery of forelimb movement."Over the last month, Geron stock remains negative by -11%. Though unimpressive, it is still on par with the Stem Cell Stocks Index, which is trailing the S&P 500 by -14% for the period.StemCells (NASDAQ: ...Click here to read the whole Article (external link)
STEMCELLS INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
DALLAS, Nov. 12, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring StemCells Inc. (Nasdaq:STEM - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. The investment report on StemCells Inc. (Nasdaq:STEM - News) should be of particular interest to other biopharmaceutical companies: Advanced Cell Technologies Inc. (OTCBB:ACTC - News), Geron Corp. (Nasdaq:GERN - News), Genzyme Corp. (Nasdaq:...Click here to read the whole Article (external link)
Would you like to leave a comment about StemCells, Inc. STEM
Find out what social network information about StemCells, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides StemCells, Inc. there is more great information available at Realpennies.com